Advertisement

Innovative Treatment Strategies for High-Grade Gliomas

  • Charles A. Conrad
  • Amy B. Heimberger
Part of the M. D. Anderson Cancer Care Series book series (MDCCS)

Keywords

Malignant Glioma Median Survival Duration Signal Transduction Inhibitor Cellular Immunotherapy Innovative Treatment Strategy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Archer GE, Bigner DD, Friedman AH, Heimberger AB, Sampson J. Induction of CD4 and CD8 T cells to the tumor-specific antigen EGFRvIII. 15th International Conference on Brain Tumor Research and Therapy. Sorrento, Italy. May 24–27, 2003. [Abstract] Neuro-Oncology 2003;5:5.Google Scholar
  2. Bloom HJ, Peckham MJ, Richardson AE, Alexander PA, Payne PM. Glioblastoma multiforme: a controlled trial to assess the value of specific active immunotherapy in patients treated by radical surgery and radiotherapy. Br J Cancer 1973;27: 253–267.PubMedGoogle Scholar
  3. Brooks WH, Markesbery WR, Gupta GD, Roszman TL. Relationship of lymphocyte invasion and survival of brain tumor patients. Ann Neurol 1978;4:219–224.PubMedCrossRefGoogle Scholar
  4. Cserr HF, DePasquale M, Harling-Berg CJ, Park JT, Knopf PM. Afferent and efferent arms of the humoral immune response to CSF-administered albumins in a rat model with normal blood-brain barrier permeability. J Neuroimmunol 1992; 41:195–202.PubMedCrossRefGoogle Scholar
  5. Dresemann G. Temozolomide/pegylated liposomal doxorubicin (PLD) in progressive glioblastoma multiforme (GBM). In: Abstracts from the World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology. May 5–8, 2005. Edinburgh, United Kingdom. [Abstract 112] Society of Neuro-Oncology, 2005:310.Google Scholar
  6. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66:3294–3302.PubMedCrossRefGoogle Scholar
  7. Folkman J. Tumor angiogenesis. [Review] Adv Cancer Res 1974;19:331–358.PubMedCrossRefGoogle Scholar
  8. Folkman J. From the lab to the clinic: one investigator's journey. J Law Med Ethics 2002;30:361–366.PubMedCrossRefGoogle Scholar
  9. Folkman J. Fundamental concepts of the angiogenic process. [Review] Curr Mol Med 2003;3:643–651.PubMedCrossRefGoogle Scholar
  10. Goudar R, Shi Q, Hjelmeland M, et al. Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 2005;4:101–112.PubMedGoogle Scholar
  11. Groves M, Puduvalli V, Conrad CA, et al. Matrix metalloproteinase inhibitor-induced joint-related toxicity predicts prolonged progression-free survival in recurrent high-grade glioma trials. In: Abstracts from the World Federation of Neuro-Oncology Second Quadrennial Meeting and the Sixth Meeting of the European Association for Neuro-Oncology. May 5–8, 2005. Edinburgh, United Kingdom. [Abstract 143] Society of Neuro-Oncology, 2005:318.Google Scholar
  12. Groves M, Puduvalli V, Hess K, et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. J Clin Oncol 2002;20:1383–1388.PubMedCrossRefGoogle Scholar
  13. Hanahan D, Weinberg R. The hallmarks of cancer. Cell 2000;100:57–70.PubMedCrossRefGoogle Scholar
  14. Heimberger A, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res 2005;11:1462–1466.PubMedCrossRefGoogle Scholar
  15. Heimberger AB, Crotty LE, Archer GE, et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003;9:4247–4254.PubMedGoogle Scholar
  16. Hickey WF, Hsu BL, Kimura H. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991;28:254–260.PubMedCrossRefGoogle Scholar
  17. Hussain SF, Yang D, Suki D, Aldape K, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses. Neuro-Oncology 2006;8:261–279.PubMedCrossRefGoogle Scholar
  18. Kleiheus P, Burger P, Plate K, Ohgaki H, Cavenee W. Astrocytic tumors. In: Kleihues P, Cavenee W, eds. Pathology and Genetics: Tumors of the Nervous System. Vol. 1. Lyon, France: International Agency for Research on Cancer; 1997.Google Scholar
  19. Kunwar S. Convection enhanced delivery of IL13-PE38QQR for treatment of recurrent malignant glioma: presentation of interim findings from ongoing phase 1 studies. Acta Neurochir Suppl 2003;88:105–111.PubMedGoogle Scholar
  20. Kurpad SN, Zhao XG, Wikstrand CJ, Batra SK, McLendon RE, Bigner DD. Tumor antigens in astrocytic gliomas. [Review] Glia 1995;15:244–256.PubMedCrossRefGoogle Scholar
  21. Levin V, Silver P, Hannigan J, et al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 1990;18:321–324.PubMedGoogle Scholar
  22. Lu Y, Wang H, Mills G. Targeting PI3K-AKT pathway for cancer therapy. Rev Clin Exp Hematol 2003;7:205–228.PubMedGoogle Scholar
  23. McCarthy B, Surawicz T, Bruner J, Kruchko C, Davis F. Consensus Conference on Brain Tumor Definition for registration. Neuro-oncology 2002;4:134–145.PubMedCrossRefGoogle Scholar
  24. Palma L, Di Lorenzo N, Guidetti B. Lymphocytic infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate, and relevance to prognosis in 228 operated cases. J Neurosurg 1978;49:854–861.PubMedCrossRefGoogle Scholar
  25. Plautz G, Miller D, Barnett G, et al. T cell adoptive immunotherapy of newly diagnosed gliomas. Clin Cancer Res 2000;6:2209–2218.PubMedGoogle Scholar
  26. Prados M, Levin V. Biology and treatment of malignant glioma. Semin Oncol 2000;27:1–10.PubMedGoogle Scholar
  27. Rasheed BK, Wiltshire RN, Bigner SH, Bigner DD. Molecular pathogenesis of malignant gliomas. [Review] Curr Opin Oncol 1999;11:162–167.PubMedCrossRefGoogle Scholar
  28. Reardon DA, Akabani G, Coleman RE, et al. Phase II trial of murine 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol 2002;20:1389–1397.PubMedCrossRefGoogle Scholar
  29. Safdari H, Hochberg F, Richardson E. Prognostic value of round cell (lymphocyte) infiltration in malignant gliomas. Surg Neurol 1985;23:221–226.PubMedCrossRefGoogle Scholar
  30. Salazar A, Levy H, Ondra S, et al. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 1996;38:1096–1103; Discussion 1103–1104.PubMedCrossRefGoogle Scholar
  31. Sampson JH, Crotty LE, Lee S, et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc Natl Acad Sci U S A 2000;97: 7503–7508.PubMedCrossRefGoogle Scholar
  32. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15:356–362.PubMedCrossRefGoogle Scholar
  33. Stupp R, Mason W, van den Bent M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987–996.PubMedCrossRefGoogle Scholar
  34. Talapatra S, Thompson C. Growth factor signaling in cell survival: implications for cancer treatment. J Pharmacol Exp Ther 2001;298:873–878.PubMedGoogle Scholar
  35. Traxler P, Allegrini P, Brandt RM, et al. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Cancer Res 2004;64:4931–4941.PubMedCrossRefGoogle Scholar
  36. Trouillas P. Immunology and immunotherapy of cerebral tumors. Current status. Rev Neurol (Paris) 1973;128:23–38.Google Scholar
  37. Tucker GC. Alpha v integrin inhibitors and cancer therapy. Curr Opin Investig Drugs 2003;4:723–731.Google Scholar
  38. Ueki K, Ono Y, Henson JW, Efird JT, von Deimling A, Louis DN. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res 1996;56:150–153.PubMedGoogle Scholar
  39. Vinkemeier U. Getting the message across, STAT! Design principles of a molecular signaling circuit. J Cell Biol 2004;167:197–201.PubMedCrossRefGoogle Scholar
  40. von Deimling A, Eibl R, Ohgaki H, et al. p53 mutations are associated with 17p allelic loss in grade II and grade III astrocytoma. Cancer Res 1992; 52:2987–2990.Google Scholar
  41. von Hanwehr RI, Hofman FM, Taylor CR, Apuzzo ML. Mononuclear lymphoid populations infiltrating the microenvironment of primary CNS tumors. Characterization of cell subsets with monoclonal antibodies. J Neurosurg 1984;60:1138–1147.CrossRefGoogle Scholar
  42. Warburg O. On the origin of cancer cells. Science 1956;123:309–314.PubMedCrossRefGoogle Scholar
  43. Wheeler CJ, Das A, Liu G, Yu J, Black K. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004;10: 5316–5326.PubMedCrossRefGoogle Scholar
  44. Wikstrand CJ, Bigner DD. Hyperimmunization of non-human primates with BCG-CW and cultured human glioma-derived cells. Production of reactive antisera and absence of EAE induction. J Neuroimmunol 1981;1:249–260.PubMedCrossRefGoogle Scholar
  45. Wikstrand CJ, Fredman P, Svennerholm L, Humphrey PA, Bigner SH, Bigner DD. Monoclonal antibodies to malignant human gliomas. [Review] Mol Chem Neuropathol 1992;17:137–146.PubMedCrossRefGoogle Scholar
  46. Yu J, Liu G, Ying H, Yong WH, Black KL, Wheeler CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004;64:4973–4979.PubMedCrossRefGoogle Scholar
  47. Yu J, Wheeler C, Zeltzer P, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001;61:842–847.PubMedGoogle Scholar
  48. Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group [published erratum appears in J Clin Oncol 1999;17:3693], J Clin Oncol 1999;17:2762–2771.Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Charles A. Conrad
  • Amy B. Heimberger

There are no affiliations available

Personalised recommendations